Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05367089
Other study ID # NL73974.068.21
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 22, 2022
Est. completion date April 22, 2027

Study information

Verified date May 2022
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months. The study ends after 252 included patients completed the study.


Description:

The purpose of this study is to investigate the vaginal culture (positive or negative) after the application of a Medical Grade Honey formulation (L-Mesitran ®) in relation to the current standard of care (Fluconazole) 1 month after starting treatment in patients with RVCC. As a secondary outcome, the effects on symptoms, including redness, irritation, itching, dysuria, dyspareunia and vaginal discharge will be analyzed. In addition, the vaginal culture after 6 months maintenance application and the number of relapses within 12 months will be investigated. Moreover, information about side effects, discomfort, and quality of life will be collected and compared. The study ends after 252 included patients completed the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 252
Est. completion date April 22, 2027
Est. primary completion date April 22, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women of at least 18 years old - Recurrent vulvovaginal candidiasis (At least 3 episodes of clinical symptoms during the last year) - Clinical and microbiological diagnosis of (recurrent) vulvovaginal candidiasis at time of consultation - Capacity to understand, consent, and comply with the trial procedures Exclusion Criteria: - Mixed vaginal infections - Pregnancy or the intention to become pregnant during the study period - Women using systemic or topical antifungal medication during the last 2 weeks prior to inclusion - Known allergies or contra-indications for Fluconazole or honey - Candida with resistance for Fluconazole - Women giving breastfeeding

Study Design


Intervention

Drug:
Fluconazole
Way of administration: oral capsules. One capsule at the same day of the week. Dosage: As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole. As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months.
Device:
L-Mesitran
Way of administration: intra-vaginal application using an applicator. Dosage: As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months.

Locations

Country Name City State
Netherlands Zuyderland Medical Centre Heerlen
Netherlands MaastrichtUMC Maastricht

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Zuyderland Medical Centre

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary vaginal swab The main study parameter is the mycological cure rate after one month of therapy for both the treatment (L-Mesitran) and control (Diflucan) groups. The vaginal swab will be analyzed in the laboratory to determine the presence or absence of microorganisms and thus the mycological cure rate. 1 month
Primary vaginal swab The main study parameter is the mycological cure rate after one month of therapy for both the treatment (L-Mesitran) and control (Diflucan) groups. However, the long term cure (after 6 months) will also be evaluated using vaginal swabs in which the presence or absence of microorganisms will be analyzed in the laboratory (mycological cure). 6 months
Primary vaginal swab The main study parameter is the mycological cure rate after one month of therapy for both the treatment (L-Mesitran) and control (Diflucan) groups. However, the long term cure (after 6 months) will also be evaluated using vaginal swabs in which the presence or absence of microorganisms will be analyzed in the laboratory (mycological cure). 12 months
Secondary Quality of life will be determined with questionnaires The secondary objectives are to investigate the effects of both treatments on the symptoms, including redness, irritation, itching, dysuria, dyspareunia, vaginal discharge, after 1, 6, 9, and 12 months of therapy. In addition, the prophylactic activity after 6 months maintenance treatment, and the long-term efficacy as number of relapses within 12 months will be investigated. These parameters will be evaluated using the questionnaires asking the severity, frequency and duration of each parameter. 1 month
Secondary Quality of life will be determined with questionnaires The secondary objectives are to investigate the effects of both treatments on the symptoms, including redness, irritation, itching, dysuria, dyspareunia, vaginal discharge, after 1, 6, 9, and 12 months of therapy. In addition, the prophylactic activity after 6 months maintenance treatment, and the long-term efficacy as number of relapses within 12 months will be investigated. These parameters will be evaluated using the questionnaires asking the severity, frequency and duration of each parameter. 6 months
Secondary Quality of life will be determined with questionnaires The secondary objectives are to investigate the effects of both treatments on the symptoms, including redness, irritation, itching, dysuria, dyspareunia, vaginal discharge, after 1, 6, 9, and 12 months of therapy. In addition, the prophylactic activity after 6 months maintenance treatment, and the long-term efficacy as number of relapses within 12 months will be investigated. These parameters will be evaluated using the questionnaires asking the severity, frequency and duration of each parameter.These parameters will be evaluated using the questionnaires asking the severity, frequency and duration of each parameter. 9 months
Secondary Quality of life will be determined with questionnaires The secondary objectives are to investigate the effects of both treatments on the symptoms, including redness, irritation, itching, dysuria, dyspareunia, vaginal discharge, after 1, 6, 9, and 12 months of therapy. In addition, the prophylactic activity after 6 months maintenance treatment, and the long-term efficacy as number of relapses within 12 months will be investigated. These parameters will be evaluated using the questionnaires asking the severity, frequency and duration of each parameter. 12 months
Secondary Side effects of medication will be determined with questionnaires Information about side effects, discomfort, quality of life and therapy compliance for both treatments will be collected and compared. These parameters will be evaluated using the questionnaires (open questions). 1 month
Secondary Side effects of medication will be determined with questionnaires Information about side effects, discomfort, quality of life and therapy compliance for both treatments will be collected and compared. These parameters will be evaluated using the questionnaires (open questions). 6 months
Secondary Side effects of medication will be determined with questionnaires Information about side effects, discomfort, quality of life and therapy compliance for both treatments will be collected and compared. These parameters will be evaluated using the questionnaires (open questions). 9 months
Secondary Side effects of medication will be determined with questionnaires Information about side effects, discomfort, quality of life and therapy compliance for both treatments will be collected and compared. These parameters will be evaluated using the questionnaires (open questions). 12 months
See also
  Status Clinical Trial Phase
Completed NCT02971007 - Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Phase 2
Completed NCT02251093 - Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Phase 3
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Not yet recruiting NCT04626258 - Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis Phase 4
Completed NCT02733432 - RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Phase 2
Completed NCT02248506 - Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Phase 4
Completed NCT02730494 - Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Phase 1
Completed NCT02180828 - Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Phase 4
Recruiting NCT04930107 - Vulvovaginal Candidiasis in Canadian Females Early Phase 1
Withdrawn NCT03167957 - Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Phase 2
Terminated NCT02859493 - Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis N/A
Completed NCT01891331 - A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Phase 2
Completed NCT02888197 - Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization N/A
Completed NCT03975569 - Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis N/A
Recruiting NCT05059145 - A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Phase 2
Recruiting NCT03075046 - Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial N/A